How the dismantling of USAID birthed a new model of health diplomacy where HIV treatment comes with mining concessions—and why Africa is pushing back
Executive Summary
- The Trump administration has replaced PEPFAR's multilateral framework with bilateral "America First" health agreements, conditioning billions in HIV/AIDS funding on mining access, health data extraction, and pathogen-sharing commitments spanning up to 25 years.
- Zimbabwe has rejected its $367 million deal outright, Zambia is resisting worse-than-average terms on a $1 billion package, and Kenya's agreement faces a High Court suspension—creating the first organized pushback against transactional health diplomacy.
- With 1.2 million Zimbabweans on US-funded HIV treatment and millions more across the continent dependent on American health financing, the standoff represents a collision between sovereignty and survival that could reshape global health governance for decades.
Chapter 1: The Architecture of a New Health Order
For two decades, the President's Emergency Plan for AIDS Relief (PEPFAR) stood as perhaps the most consequential achievement of American soft power in the 21st century. Launched by George W. Bush in 2003, the program channeled over $110 billion into combating HIV/AIDS across 55 countries, saving an estimated 25 million lives. It operated through a web of implementing partners—NGOs, faith-based organizations, universities, and multilateral institutions—that delivered antiretroviral treatment to those who needed it regardless of geopolitical calculation.
That architecture is now gone.
The dismantling of USAID in early 2025, followed by the Trump administration's December announcement of an "America First Global Health Strategy," replaced this multilateral ecosystem with something fundamentally different: bilateral memoranda of understanding (MOUs) negotiated directly between Washington and recipient governments. The State Department's Bureau of Global Health Security and Diplomacy now manages what was once the domain of development professionals.
As of February 2026, 16 African countries have signed these new bilateral agreements, committing to a combined $18 billion framework—though recipient countries themselves must contribute roughly $7.1 billion of that total. The underlying logic is straightforward: countries must invest more in their own health sectors, performance targets must be met, and American taxpayer dollars must "demonstrably advance American national interests."
The devil, as always, is in the details.
Chapter 2: The Zambian Gambit—Health for Minerals
A leaked draft of Zambia's five-year MOU, obtained by the Guardian in February 2026, reveals what advocates call the starkest example of transactional health diplomacy. The headline numbers appear generous: $1.012 billion in US health funding over five years, in exchange for Zambia hiring 40,000 new health workers, contributing an additional $400 million in health spending, and meeting performance targets on HIV enrollment and maternal mortality reduction.
But beneath this framework lies a web of conditions that distinguish Zambia's deal from the 16 already signed.
The mining clause. In early December 2025, the US embassy in Lusaka confirmed that health financing was contingent on "collaboration in the mining sector and clear business-sector reforms" that would improve US economic access to the country. Zambia sits atop vast copper and cobalt reserves—critical minerals for the energy transition and AI infrastructure buildout that Washington has designated as strategic priorities.
The data extraction. Zambia's MOU requires sharing health data with the US for 10 years—far exceeding the seven-year commitment extracted from Kenya. More dramatically, it commits Zambia to sharing information on new or emerging pathogens within its borders for 25 years. No other publicly available MOU includes such a long-term pathogen data pledge.
The monthly briefings. The Zambian government must provide the US embassy with monthly briefings on trade and investment efforts between the two countries, with a stated goal "of expanding US commercial investment in Zambia."
The termination clause. If Zambia falters on any performance metric, Washington can terminate the agreement and withdraw all funds. Given that the country's entire 2026 health budget is approximately $1.3 billion and more than a third of its national budget goes to debt repayments, the threat is existential.
The arithmetic is particularly telling. Washington had committed $367 million to Zambia for HIV services alone in the previous year. Under the new MOU, total health funding for 2026 drops to $320 million—covering not just HIV but also malaria, TB, and disease surveillance. The overall five-year commitment of $1.012 billion is lower than the $1.5 billion figure Zambia's then-health minister Elijah Muchima announced in November 2025.
On February 15, Muchima went on television to deny that health financing was linked to mining concessions. "If there are other external conditions attached, I am personally not part of that," he said. President Hakainde Hichilema fired him three days later without explanation.
Asia Russell, director of Health GAP, the HIV advocacy organization, was blunt: "The US is conditioning life-saving health services on plundering the mineral wealth of the country. It's shameless exploitation."
Chapter 3: Zimbabwe's Rebellion—Sovereignty Over Survival
While Zambia continues to negotiate under an April 1 deadline, Zimbabwe chose a different path. A leaked government memo from December 2025 revealed that President Emmerson Mnangagwa found the proposed $367 million deal "lopsided" and directed negotiations to be terminated.
The sticking point: comprehensive access to Zimbabwe's sensitive health data, including virus samples and epidemiological information. Government spokesperson Nick Mangwana laid out the case with unusual clarity:
"Zimbabwe was being asked to share its biological resources and data over an extended period, with no corresponding guarantee of access to any medical innovations—such as vaccines, diagnostics, or treatments—that might result from that shared data. In essence, our nation would provide the raw materials for scientific discovery without any assurance that the end products would be accessible to our people should a future health crisis emerge."
He added a detail that underscored the asymmetry: "The United States was not offering reciprocal sharing of its own epidemiological data with our health authorities."
The consequences were immediate. US Ambassador Pamela Tremont announced Washington would "turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe." The US has been Zimbabwe's largest bilateral health donor for two decades, providing nearly $2 billion since 2006. It is "directly responsible," by its own admission, for Zimbabwe reaching UN targets for HIV treatment, testing, and viral load suppression.
The 1.2 million Zimbabweans currently receiving HIV treatment through US-supported programs now face an uncertain future. Zimbabwe had recently begun rolling out lenacapavir—a breakthrough long-acting HIV prevention drug administered twice yearly—under PEPFAR partnership with the Global Fund. That rollout is now in jeopardy.
The Zimbabwe College of Public Health Physicians warned: "An abrupt discontinuation of such support could risk treatment interruption, increased transmission, the emergence of drug resistance, and additional strain on the health system."
Chapter 4: The Broader Rebellion—Kenya, Courts, and Continental Resistance
Zimbabwe and Zambia are not alone. In Kenya, a $1.6 billion five-year agreement signed in December 2025 has been suspended by the High Court after activist Okiya Omtatah filed a case citing concerns about data safety, lack of parliamentary oversight, and terms that could strain the national budget. Kenya's agreement limited health data sharing to seven years—better than Zambia's proposed terms, but still enough to trigger legal challenge.
The pattern emerging across the continent reveals a tension that the "America First" framework did not anticipate: recipient countries with functioning judiciaries, active civil societies, and increasingly assertive legislatures are treating health MOUs as sovereignty issues, not aid compliance exercises.
This represents a fundamental shift. For decades, PEPFAR operated with minimal sovereignty friction because it worked through implementing partners rather than government-to-government agreements that require parliamentary ratification or judicial review. By moving to bilateral deals, the Trump administration inadvertently created legal and political attack surfaces that didn't previously exist.
Meanwhile, the countries that have signed—16 African nations representing the bulk of US health investment on the continent—have largely done so quietly. The terms of most agreements remain confidential, though the Center for Global Development has analyzed publicly available MOUs and found significant variation in conditions, suggesting countries with greater bargaining power secured better terms.
| Country | Deal Value | Data Sharing | Mining/Trade Linkage | Status |
|---|---|---|---|---|
| Zimbabwe | $367M / 5yr | Rejected | N/A | Collapsed |
| Zambia | $1.012B / 5yr | 10yr + 25yr pathogen | Mining + monthly briefings | Negotiating (April 1 deadline) |
| Kenya | $1.6B / 5yr | 7yr | Unknown | Court-suspended |
| 16 other nations | ~$18B combined | Varies | Varies | Signed |
Chapter 5: Scenario Analysis—The Future of Transactional Health Diplomacy
Scenario A: Compliance and Coercion (45%)
Premise: Most African countries accept the new framework with minor modifications. Zambia signs by April 1 under pressure. Zimbabwe becomes an isolated case.
Evidence:
- 16 of 19 negotiating countries have already signed, suggesting the coercive framework works for the majority
- PEPFAR's 2003-2025 track record of compliance: countries historically accepted conditions to maintain HIV programs
- Zambia's debt burden (33%+ of budget) limits negotiating leverage
- April 1 termination deadline creates time pressure
Trigger: Zambia's civil society fails to secure court intervention; Zimbabwe's HIV metrics deteriorate visibly
Historical precedent: Structural adjustment programs of the 1980s-90s, where IMF/World Bank conditionality was widely accepted despite sovereignty concerns because alternatives were worse
Investment implication: Limited market impact; mining companies with Zambian exposure (First Quantum, Barrick) may benefit from improved US access terms
Scenario B: Organized African Resistance (35%)
Premise: Zimbabwe's rejection emboldens other countries. Kenya's court challenge succeeds and creates legal precedent. AU or SADC coordinates collective bargaining position.
Evidence:
- AU's February 2026 summit already addressed US aid conditionality
- Zimbabwe's Mnangagwa framing the issue as sovereignty resonates with post-colonial narrative
- Kenya's High Court suspension demonstrates judicial independence
- China's February 2026 zero-tariff policy for 53 African nations provides alternative partnership model
- WHO withdrawal removes US from multilateral health governance, weakening normative authority
Trigger: Second or third country publicly rejects deal; AU passes resolution on health data sovereignty
Historical precedent: 2001 Doha Declaration on TRIPS, when developing countries collectively forced pharmaceutical patent flexibilities for public health emergencies
Investment implication: Increased uncertainty for US mining/pharma companies in Africa; Chinese health infrastructure investments accelerate; WHO alternatives gain traction
Scenario C: Health Crisis Forces Renegotiation (20%)
Premise: Treatment interruptions in Zimbabwe lead to measurable HIV resurgence, creating political pressure on Washington to soften terms. A pandemic-potential pathogen emerges, exposing the gap in US surveillance coverage.
Evidence:
- Zimbabwe's 1.2 million HIV patients represent a potential public health catastrophe
- Drug resistance from treatment interruption could create regional spillover
- US withdrawal from WHO already created surveillance blind spots
- 25-year pathogen data demands suggest Washington recognizes its own vulnerability
Trigger: Zimbabwe reports treatment-resistant HIV cluster; avian influenza variant detected in African country without US surveillance partnership
Historical precedent: 2014 Ebola crisis, which forced Obama administration to massively expand health engagement despite political reluctance
Investment implication: Pharmaceutical companies with Africa exposure face demand disruption followed by emergency procurement surge; global health security stocks volatile
Chapter 6: The Deeper Architecture—Why This Matters Beyond Africa
The transformation of American health diplomacy from altruistic soft power to transactional extraction reveals something important about the broader restructuring of the global order in 2026.
The resource nexus. Linking health funding to mining access in Zambia makes explicit what was always implicit in great power engagement with resource-rich developing countries. The difference is one of institutional honesty—or institutional cynicism, depending on your perspective. PEPFAR's humanitarian framework allowed the US to maintain mineral access, trade relationships, and intelligence cooperation with African governments while keeping these arrangements in separate institutional lanes. The new bilateral MOUs collapse these distinctions.
The data frontier. The 25-year pathogen data commitment demanded from Zambia points to what may be the most consequential dimension of these agreements. In a post-pandemic world, genomic surveillance data and pathogen libraries are strategic assets. The US withdrawal from WHO eliminated its access to the Pathogen Access and Benefit Sharing system—the multilateral mechanism designed to ensure equitable distribution of benefits from shared biological data. These bilateral MOUs are, in part, an attempt to rebuild that intelligence capability on purely American terms.
The sovereignty paradox. The countries most dependent on US health financing are the least able to resist its conditions. But the countries that resist—Zimbabwe, with its history of defiance toward Western institutions, or Kenya, with its robust judiciary—may inadvertently create the political and legal frameworks that protect the rest of the continent.
Chapter 7: Investment Implications
Healthcare and pharma: Treatment interruptions in Zimbabwe and potentially Zambia create short-term disruption for generic drug suppliers (Cipla, Aurobindo, Mylan) with African distribution. Long-term, the shift from PEPFAR's implementing partner model to government-to-government agreements disrupts the $6+ billion annual market for HIV/AIDS procurement.
Mining and critical minerals: Zambia's copper belt remains a prize. If the health-mining linkage succeeds, US companies gain preferential access to an estimated 28 million tonnes of copper reserves. First Quantum Minerals (FM.TO), which operates Zambia's largest copper mine, and Barrick Gold are direct beneficiaries. If the deal collapses, Chinese mining companies already present in Zambia (CNMC, China Minmetals) fill the vacuum.
Global health infrastructure: The retreat of US multilateral health engagement creates space for alternative architectures. China's health BRI, the African Union's Africa CDC, and the Wellcome Trust's pandemic preparedness fund all stand to gain prominence. Bond investors should watch for sovereign credit implications in countries that lose US health funding—Zimbabwe's already-fragile public finances face additional pressure.
Conclusion
The transformation of American health aid from humanitarian investment to transactional extraction is not simply a policy shift—it is a fundamental rewriting of the social contract between the world's richest country and some of its most vulnerable populations. For 20 years, PEPFAR demonstrated that saving lives at scale was possible when political will met institutional capacity. The 25 million lives saved were real.
What comes next is uncertain. Zimbabwe's rebellion may prove quixotic—a defiant gesture by a government with few alternatives. Or it may become the first domino in a broader renegotiation of the terms on which the Global South accepts American engagement. The answer will depend on whether African solidarity proves stronger than African desperation, and whether the 1.2 million people on HIV treatment in Zimbabwe alone can afford to wait for that question to be resolved.
The deadline is April 1. The clock is ticking.
Leave a Reply